Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1163124 Target Snapshot

Mitogen-activated protein kinase kinase kinase 13 · SINGLE PROTEIN · Homo sapiens

278Compounds
75Assays
8Approved Drugs
112.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Mitogen-activated protein kinase kinase kinase 13 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O43283. Start with Parkinson disease, then reuse UniProt O43283 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Parkinson disease, then reuse UniProt O43283 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Parkinson disease

Mitogen-activated protein kinase kinase kinase 13 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug remains visible in the same block.

Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase kinase kinase 13 as ChEMBL target CHEMBL1163124, mapped to UniProt O43283. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase kinase kinase 13
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1163124
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O43283
Mitogen-activated protein kinase kinase kinase 13
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase kinase kinase 13 is the right protein anchor across sources, using UniProt O43283 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Parkinson disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase kinase kinase 13
UniProt AccessionO43283
Component TypeProtein
Sequence Length966 aa

Mitogen-activated protein kinase kinase kinase 13

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase kinase kinase 13, mapped to UniProt O43283. Sequence length is 966 aa.

Mapped IDO43283
Review nameMitogen-activated protein kinase kinase kinase 13
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Mitogen-activated protein kinase kinase kinase 13 shows clinical signal disease relevance led by Parkinson disease.

Clinical signal Phase II
Parkinson disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCEP-1347
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseParkinson disease
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
2
Phase III
3
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC5028.0
KD84.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5286166 8.7 IC50 2.0 Preclinical
CHEMBL3393333 8.52 IC50 3.0 Preclinical
CHEMBL5268969 8.22 IC50 6.0 Preclinical
CHEMBL5271665 8.22 IC50 6.0 Preclinical
CHEMBL5271972 8.15 IC50 7.0 Preclinical
CHEMBL5270353 8.05 IC50 9.0 Preclinical
CHEMBL5287658 8.0 IC50 10.0 Preclinical
CHEMBL5272522 7.89 IC50 13.0 Preclinical
CHEMBL3732012 7.85 IC50 14.0 Preclinical
CHEMBL1230609 7.8 Kd 16.0 Clinical
Distribution

pChEMBL Value Distribution

1
5.0
3
5.5
12
6.0
11
6.5
12
7.0
6
7.5
5
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
NERATINIB
CHEMBL180022
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

75
Total Assays
49
Tested Compounds
1
Assay Types
Binding — 75 assays, 49 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 53 25 6.6
assay format 15 0
cell-based format 7 24 7.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine